tenapanor

10/28/2021 - "This trial assessed the safety and efficacy of tenapanor for the management of hyperphosphatemia. "
11/01/2023 - "Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study."
01/01/2022 - "The search term "tenapanor hyperphosphatemia" was used for study retrieval. "
06/01/2017 - "Additional studies are required to clarify the optimal dosing of tenapanor in patients with CKD-related hyperphosphatemia."
11/01/2023 - "Tenapanor as Add-on Treatment for Hyperphosphatemia in Dialysis Patients: Enough Bang for the Buck?"

01/01/2021 - "Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)."
01/01/2020 - "Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)."
11/01/2023 - "Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study."
01/01/2017 - "This study assessed the efficacy and safety of tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). "
01/01/2017 - "Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial."

01/01/2021 - "Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)."
01/01/2020 - "Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)."
11/01/2023 - "Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study."
01/01/2017 - "This study assessed the efficacy and safety of tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). "
01/01/2017 - "Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial."

01/01/2022 - "Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease."
01/01/2022 - "This narrative review explores the currently published studies that have evaluated tenapanor for the treatment of hyperphosphatemia in end-stage kidney disease (ESKD) patients on hemodialysis. "
05/01/2015 - "Tenapanor, a minimally systemically available inhibitor of the intestinal sodium-hydrogen exchanger 3, is being evaluated in clinical trials for its potential to (1) lower gastrointestinal sodium absorption, (2) improve fluid overload-related symptoms, such as hypertension and proteinuria, in patients with CKD, and (3) reduce interdialytic weight gain and intradialytic hypotension in ESRD. "

03/01/2020 - "Tenapanor has been shown to improve bowel movement frequency/form and abdominal pain in patients with IBS-C. "
01/01/2023 - "Furthermore, tenapanor reduces intestinal permeability to improve visceral hypersensitivity and abdominal pain. "